Adaptive Biotechnologies (ADPT) to Release Earnings on Tuesday

Adaptive Biotechnologies (NASDAQ:ADPT) is expected to be releasing its earnings data after the market closes on Tuesday, February 11th. Analysts expect Adaptive Biotechnologies to post earnings of ($0.27) per share and revenue of $46.05 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Adaptive Biotechnologies Trading Down 2.1 %

ADPT stock opened at $7.84 on Monday. The company has a market capitalization of $1.16 billion, a PE ratio of -5.85 and a beta of 1.50. Adaptive Biotechnologies has a 12-month low of $2.28 and a 12-month high of $8.33. The business’s fifty day moving average price is $6.84 and its 200 day moving average price is $5.53.

Analyst Upgrades and Downgrades

ADPT has been the subject of several recent research reports. Piper Sandler raised their price target on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. BTIG Research lifted their price target on Adaptive Biotechnologies from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. Finally, The Goldman Sachs Group lifted their price target on shares of Adaptive Biotechnologies from $5.50 to $7.50 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.